Latest App Notes & Case Studies

This tech note highlights technology that switches easily between DNA and RNA analysis to ensure quick and reliable quality checks and precise sizing of DNA and IVT RNA products.

Single cell and spatial technologies that profile gene expression across whole tissues are revolutionizing the resolution of molecular states in clinical tissue samples.

The cell therapy manufacturing process requires the guidance of chemical manufacturing and controls for analytical method development focusing on the critical quality attributes (CQAs).

Pyruvate kinase is an enzyme involved in energy-supplying glycolysis and ATP synthesis, thus is pivotal for the eucaryotic energy metabolism. In addition, overexpression of pyruvate kinase is believed to play a role in cancer.

It has proven difficult to accurately identify the biological targets of cancer, which are necessary for the development of successful therapeutics including novel immunotherapies, such as those based on chimeric antigen receptor (CAR) T cells.

When it comes to cancer, diagnosis often relies on tissue biopsy in conjunction with medical imaging. In addition to sometimes being inconclusive, tissue biopsies are associated with risks, high costs and inconvenience for patients, making them ill-suited for screening or tracking disease progression.

In clinical proteomics research applications, blood plasma is the key sample of interest, but comprehensive proteome analysis can be challenging due to the large dynamic range of concentration.

Single cell analysis in a spatially resolved context is the gateway to deciphering scientific questions in various application areas. Such analysis requires the highest available spatial precision combined with highly sensitive detection.

Expansion of Specific Lymphocyte Populations With 4Cell® Nutri-T Xeno-Free, Serum-Free Medium

The success of CAR T-cell therapy requires efficient expansion of specific subpopulations of patient-derived immune cells.

There are currently more than 140 monoclonal antibodies (mAbs) approved by the FDA as biotherapeutic agents, representing the most rapidly growing class of new drugs.